• Home
  • NEW DAY MEDICINE
  • 3 (77) 2025
  • 7 -3 (77) 2025 - Sharopova M.S. - MODERN APPROACH TO THE TREATMENT OF PURULENT SURGICAL DISEASES AGAINST THE BACKGROUND OF DIFFUSE TOXIC ULCERS AND DIABETES MELLITUS

7 -3 (77) 2025 - Sharopova M.S. - MODERN APPROACH TO THE TREATMENT OF PURULENT SURGICAL DISEASES AGAINST THE BACKGROUND OF DIFFUSE TOXIC ULCERS AND DIABETES MELLITUS

MODERN APPROACH TO THE TREATMENT OF PURULENT SURGICAL DISEASES AGAINST THE BACKGROUND OF DIFFUSE TOXIC ULCERS AND DIABETES MELLITUS

Sharopova M.S. - Bukhara State Medical Institute named after Abu Ali ibn Sina

Resume

This article analyzes the clinical course of purulent surgical diseases in patients with diffuse toxic goiter and diabetes mellitus, as well as treatment methods. According to the study results, traditional surgical approaches that do not consider metabolic disorders may lead to delayed wound healing. Comprehensive therapy, including the restoration of hormonal and metabolic balance, ensured faster wound healing. These findings highlight the need to implement new approaches for treating purulent surgical diseases in the presence of diffuse toxic goiter and diabetes mellitus.

Keywords: diffuse toxic goiter, diabetes mellitus, purulent surgical diseases, metabolic disorders, comprehensive therapy, microcirculation, immunity, epithelialization.

First page

31

Last page

34

For citation:Sharopova M.S. - MODERN APPROACH TO THE TREATMENT OF PURULENT SURGICAL DISEASES AGAINST THE BACKGROUND OF DIFFUSE TOXIC ULCERS AND DIABETES MELLITUS//New Day in Medicine 3(77)2025 31-34 ttps://https://newdayworldmedicine.com/en/new_day_medicine/3-77-2025

List of References

  1. Эндокринология. Национальное руководство. Краткое издание / Под ред. И.И. Дедова, Г.А. Мельниченко. М.: ГЭОТАР-Медиа. 2013; 752 с.
  2. Якубовский С.В. Использование сукцинат содержащих препаратов в комплексном лечении пациентов с диффузным токсическим зобом / С.В. Якубовский, Г.Г. Кондратенко, И.И. Попова // УО Белорус. гос. мед. ун-та. Клиническая медицина. 2014;8:50-53.
  3. Abe S., Namba N., Abe M., Fujiwara M., Aikawa T., Kogo M. & Ozono K. Monocarboxylate Transporter 10 Functions as a Thyroid Hormone Transporter in Chondrocytes // Endocrinology. 2012;153:40-49.
  4. Ale A.O., Ogbera A.O., Ebili H.O., Adeyemo O.L., Afe T.O. Prevalence, Predictive Factors, and Characteristics of Osteoporosis in Hyperthyroid Patients // Int JEndocrinol. 2018;(3):1-7.
  5. Alharbi F., Ahmed M.R. Experience of Thyroid Surgery at Tertiary Referral Centers in Jazan Hospitals, Saudi Arabia // Interv. Med. Appl. Sci. 2018 Dec;10(4): P. 198-201.
  6. Bassett J.D., Williams G.R. Role of Thyroid Hormones in Skeletal Development and Bone Maintenance // Endocrine Reviews. 2016; 37(2):135-87.
  7. Granja C., Povoa P., Lobo C. et al. The Predisposition, infection, Response and Organ Failure (PIRO) Sepsis Classification System: Results of Hospital Mortality Using a Novel Concept and Methodological Approach // PLoS One, 2013; 8 (1):e53885.
  8. Greenblatt M.B., Tsai J.N., Wein M.N. Bone Turnover Markers in the Diagnosis Andmonitoring of Metabolic Bone Disease // Clin Chem. 2017; 63(2):464-74.
  9. Johnson M.J., Shumway N., Bivins M., Bessesen M.T. Outcomes of Limb-Sparing Surgery for Osteomyelitis in the Diabetic Foot: Importance of the Histopathologic Margin // Open Forum Infect Dis. 2019, Sep 10;6(10):ofz382
  10. Ju H., Kim T., Chung C.M., Park J., Nikawa T., Park K., et al. Metabolic Suppression by 3-Iodothyronamine Induced Muscle cell Atro phy Via Activation of Foxo-proteasome Signaling and Downregulation of Akt1-S6K Signaling // Biol. pharm. Bull., 2017; 576:576-82. doi: 10.1248/bpb. b16-00653

    file

    download